Stockscreener 앱 받기
1.33
3.62%
-0.05
시간 외 거래:
1.29
-0.04
-3.01%
전일 마감가:
$1.38
열려 있는:
$1.35
하루 거래량:
1.35M
Relative Volume:
0.48
시가총액:
$94.58M
수익:
$391.70K
순이익/손실:
$-52.34M
주가수익비율:
-1.7733
EPS:
-0.75
순현금흐름:
$-45.92M
1주 성능:
-10.74%
1개월 성능:
-27.72%
6개월 성능:
+311.00%
1년 성능:
+12.71%
1일 변동 폭
$1.275
$1.35
1주일 범위
$1.275
$1.53
52주 변동 폭
$0.2425
$2.01
Ovid Therapeutics Inc Stock (OVID) Company Profile
명칭
Ovid Therapeutics Inc
전화
212-776-4381
주소
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
OVID을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
1.33 | 98.13M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-09 | 개시 | Oppenheimer | Outperform |
| 2025-08-08 | 재개 | B. Riley Securities | Buy |
| 2024-06-18 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-04-30 | 개시 | B. Riley Securities | Buy |
| 2024-04-29 | 개시 | H.C. Wainwright | Buy |
| 2024-04-05 | 개시 | Wedbush | Outperform |
| 2023-12-21 | 개시 | BTIG Research | Buy |
| 2023-10-13 | 개시 | Oppenheimer | Outperform |
| 2021-04-20 | 다운그레이드 | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-02 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | 개시 | RBC Capital Mkts | Outperform |
| 2018-04-20 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Ovid Therapeutics Inc 주식(OVID)의 최신 뉴스
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Yahoo Finance
Published on: 2025-11-04 05:50:05 - newser.com
Regression analysis insights on Ovid Therapeutics Inc. performanceWeekly Trade Review & Safe Entry Trade Signal Reports - newser.com
Long term hold vs stop loss in Ovid Therapeutics Inc.CEO Change & AI Driven Price Predictions - newser.com
Visual analytics tools that track Ovid Therapeutics Inc. performance2025 Market Overview & Safe Entry Momentum Stock Tips - newser.com
Can trapped investors hope for a rebound in Ovid Therapeutics Inc.Market Weekly Review & Daily Volume Surge Signals - newser.com
Visual trend scoring systems applied to Ovid Therapeutics Inc.Insider Selling & Technical Pattern Based Buy Signals - newser.com
How Ovid Therapeutics Inc. (1OT) stock correlates with oil marketsJuly 2025 Intraday Action & AI Driven Stock Movement Reports - newser.com
Using flow based indicators on Ovid Therapeutics Inc.Trade Entry Report & Verified Swing Trading Watchlist - newser.com
What MACD trends signal for Ovid Therapeutics Inc. (1OT) stockQuarterly Growth Report & Capital Efficient Trading Techniques - newser.com
What analysts say about Ovid Therapeutics Inc 1OT stockSector Leadership Analysis & Low Risk Capital Appreciation - earlytimes.in
Combining machine learning predictions for Ovid Therapeutics Inc.Watch List & Technical Buy Zone Confirmation - newser.com
Is Ovid Therapeutics Inc. stock a safe haven assetWeekly Gains Summary & Scalable Portfolio Growth Methods - newser.com
Is Ovid Therapeutics Inc. (1OT) stock protected from inflation2025 Breakouts & Breakdowns & Safe Entry Zone Tips - newser.com
How strong is Ovid Therapeutics Inc. stock balance sheetJuly 2025 Sector Moves & Stepwise Entry/Exit Trade Alerts - newser.com
Short Interest in Ovid Therapeutics (NASDAQ:OVID) Grows By 463.2% - MarketBeat
Ovid Therapeutics Raises $175 Million Through PIPE Financing - Finimize
Ovid Therapeutics (OVID) Price Target Increased by 22.06% to 4.23 - Nasdaq
Quarterly Recap: How Ovid Therapeutics Inc. stock compares to industry benchmarksEarnings Summary Report & Weekly Sector Rotation Insights - fcp.pa.gov.br
OVID PRE 14A: approvals for Series B conversion and warrants - Stock Titan
Ovid Therapeutics Inc (OVID) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):